Contents
Short Description: A routine glucose test can show whether blood sugar is high, normal, or low at one point in time. But it may not explain how hard the body is working to keep glucose controlled. HOMA2-IR, HOMA2-%B, and HOMA2-%S help estimate insulin resistance, beta-cell output, and insulin sensitivity when reviewed with fasting glucose, insulin, C-peptide, triglycerides, and related metabolic markers.
A routine fasting glucose test can show whether your blood sugar is high, normal, or low at one moment in time. But it may not explain why that glucose result looks the way it does.
Two people can have the same fasting glucose result but very different metabolic patterns. One person may be maintaining normal glucose by producing more insulin. Another may have reduced insulin sensitivity. Another may have a pancreatic output issue that is not obvious from glucose alone.
That is where HOMA2-IR, HOMA2-%B, and HOMA2-%S can help provide a more complete picture. These calculated markers are part of the updated Homeostasis Model Assessment, or HOMA2, which estimates insulin resistance, beta-cell function, and insulin sensitivity from fasting glucose with fasting insulin or C-peptide.
Ulta Lab Tests provides access to many lab tests that can help patients and healthcare providers better understand glucose and insulin-related patterns. Lab testing is informational and should be reviewed with a qualified healthcare provider. It should not be used as a stand-alone diagnosis or as a substitute for medical advice.
HOMA stands for Homeostasis Model Assessment. It is a mathematical model used to estimate how the glucose-insulin feedback system is functioning.
The original HOMA model used fasting glucose and fasting insulin to estimate insulin resistance and beta-cell function. HOMA2 is the updated model. It uses more complex nonlinear calculations and can use fasting insulin or C-peptide as inputs.
HOMA2-IR estimates insulin resistance. Insulin resistance means the body’s cells are not responding to insulin as efficiently as expected. When insulin resistance increases, the pancreas may need to produce more insulin to help move glucose from the blood into cells.
HOMA2-%B estimates beta-cell function. Beta cells are specialized cells in the pancreas that produce insulin. This marker helps estimate how much insulin-producing activity may be occurring relative to the glucose level.
A higher HOMA2-%B does not always mean the pancreas is “healthier.” In some cases, it may suggest compensation. In other cases, it must be interpreted carefully alongside glucose, insulin or C-peptide, HOMA2-IR, and HOMA2-%S.
HOMA2-%S estimates insulin sensitivity. Insulin sensitivity describes how responsive the body’s tissues are to insulin. Higher insulin sensitivity generally means the body can respond to insulin more efficiently. Lower insulin sensitivity may suggest insulin resistance.
Concise Answer: HOMA2-IR, HOMA2-%B, and HOMA2-%S are calculated markers that help estimate insulin resistance, beta-cell output, and insulin sensitivity. They are most useful when reviewed together, not as isolated numbers.
Fasting glucose is a valuable marker, but it is only one piece of the metabolic picture. In early insulin resistance, glucose may remain normal because the pancreas is producing more insulin to keep blood sugar controlled.
This is why fasting glucose alone may miss early metabolic stress. A person may have normal glucose while fasting insulin, C-peptide, triglycerides, or other metabolic markers suggest that the body is compensating.
The HOMA2 matrix helps ask a deeper question:
How hard is the body working to keep glucose in range?
That question matters because glucose regulation is connected to energy, weight patterns, cardiovascular risk, triglycerides, liver function, inflammation, and long-term metabolic health.
A fasting glucose result can look normal even when fasting insulin is high. This may happen when the pancreas is compensating for reduced insulin sensitivity by producing more insulin.
This matters because the same fasting glucose value can reflect different underlying patterns:
Concise Answer: Routine glucose testing shows blood sugar at one point in time. HOMA2 helps add context by estimating insulin resistance, beta-cell output, and insulin sensitivity.
When HOMA2-IR, HOMA2-%B, and HOMA2-%S are reviewed together with fasting glucose and triglycerides, they can help organize glucose dysregulation into pattern categories. These patterns are not diagnoses by themselves. They are educational interpretation frameworks that may help guide conversations with a healthcare provider.
| Pattern | Glucose | Triglycerides | HOMA2-%B | HOMA2-%S | HOMA2-IR | Possible Interpretation |
|---|---|---|---|---|---|---|
| Reactive hypoglycemia pattern | Normal to decreased | Decreased | Decreased | Increased | Decreased | May suggest low or unstable glucose patterns rather than classic insulin resistance. |
| Early insulin resistance pattern | Normal to increased | Increased | Increased | Decreased | Increased | May suggest beta-cell compensation while glucose is still near normal. |
| Late insulin resistance pattern | Increased | Increased | Increased, unchanged, or decreased | Significantly decreased | Increased | May suggest worsening insulin sensitivity and changing beta-cell compensation. |
| Type 2 diabetes pattern | Significantly increased | Significantly increased | Increased, unchanged, or decreased | Significantly decreased | Significantly increased | May suggest a more advanced insulin-resistance pattern. |
| Type 3c / pancreatogenic diabetes pattern | Normal to decreased | Decreased | Increased | Decreased | Decreased | May suggest a pancreatic insufficiency pattern rather than classic insulin resistance. |
A reactive hypoglycemia pattern may involve normal-to-low glucose, decreased triglycerides, decreased HOMA2-IR, decreased HOMA2-%B, and increased HOMA2-%S.
This pattern may be relevant for people who experience shakiness, sweating, hunger, irritability, dizziness, or energy crashes. This pattern should be discussed with a healthcare provider, especially if symptoms are severe, recurrent, or occur with fainting, confusion, chest pain, or neurological symptoms.
Early insulin resistance may show normal-to-slightly increased glucose, increased triglycerides, increased HOMA2-%B, decreased HOMA2-%S, and increased HOMA2-IR.
This is one of the most important patterns because fasting glucose may still look normal. The pancreas may be producing more insulin to overcome reduced insulin sensitivity. A person may not yet meet standard glucose-based thresholds for prediabetes, but the insulin-glucose feedback loop may already be changing.
Late insulin resistance may show increased glucose, increased triglycerides, significantly decreased HOMA2-%S, and increased HOMA2-IR. HOMA2-%B may be increased, unchanged, or decreased depending on whether beta cells are still compensating.
A declining HOMA2-%B in the setting of rising glucose and worsening insulin sensitivity may be clinically meaningful and should be reviewed with a healthcare provider.
A type 2 diabetes pattern may show significantly increased glucose, significantly increased triglycerides, significantly decreased HOMA2-%S, and significantly increased HOMA2-IR. HOMA2-%B may vary depending on disease stage and beta-cell reserve.
Type 3c diabetes is different from type 2 diabetes. It can occur when pancreatic damage affects the pancreas’s ability to produce insulin. This distinction matters because type 2 diabetes is commonly associated with insulin resistance, while type 3c diabetes is related to pancreatic damage or pancreatic insufficiency.
| Symptom, Risk Factor, or Pattern | What It May Suggest | Related Lab Tests That May Help Provide More Information |
|---|---|---|
| Normal fasting glucose with fatigue or weight-loss resistance | Glucose may be controlled through higher insulin output | Fasting Insulin, Fasting Glucose, HOMA-IR calculation, HOMA2 calculation, A1c, Lipid Panel |
| Afternoon energy crashes or shakiness | Possible glucose instability or hypoglycemia pattern | Fasting Glucose, Insulin, C-Peptide, A1c, provider-directed glucose monitoring |
| Increased waist circumference or metabolic syndrome risk | Possible insulin resistance or cardiometabolic risk | Fasting Insulin, Glucose, A1c, Lipid Panel, hs-CRP |
| Elevated triglycerides | May support an insulin-resistance or cardiometabolic pattern | Lipid Panel, Fasting Insulin, Glucose, A1c, ApoB |
| Family history of type 2 diabetes | Increased risk for glucose dysregulation | A1c, Fasting Glucose, Fasting Insulin, C-Peptide |
| PCOS or symptoms of androgen imbalance | May be associated with insulin resistance in some people | Fasting Insulin, Glucose, A1c, Lipid Panel, hormone testing when appropriate |
| History of pancreatitis, pancreatic surgery, or cystic fibrosis | Possible pancreatic-related glucose dysregulation | Glucose, A1c, C-Peptide, Insulin, pancreatic evaluation through a provider |
| Increased thirst, frequent urination, blurred vision | Possible elevated glucose requiring medical evaluation | Glucose, A1c, Comprehensive Metabolic Panel, urinalysis when appropriate |
Safety note: Seek urgent medical care for severe symptoms such as fainting, confusion, seizures, chest pain, severe dehydration, extreme weakness, or very high or very low glucose readings if you monitor glucose at home.
Lab testing can help reveal objective patterns that symptoms alone may not explain. For glucose and insulin regulation, testing may show:
Lab testing cannot determine the full cause of symptoms by itself. It also cannot replace a clinician’s evaluation, medical history, medication review, physical exam, or diagnostic testing when needed.
No single test should usually be interpreted in isolation. A normal fasting glucose does not always rule out insulin resistance. An abnormal value does not always mean disease. Results should be reviewed with a qualified healthcare provider.
| Lab Test or Biomarker | What It Measures | Why It May Be Relevant | Important Limitations |
|---|---|---|---|
| Fasting Glucose | Blood sugar at the time of testing | Core input for HOMA and glucose assessment | One point in time; affected by fasting status, illness, and medications |
| Fasting Insulin | Insulin level in blood | Helps evaluate insulin response and calculate HOMA-IR | Must be fasting; interpret with glucose |
| C-Peptide | Marker of the body’s own insulin production | May help assess pancreatic insulin output | Interpret with glucose, kidney function, medications, and clinical context |
| HOMA-IR | Calculated insulin resistance estimate using the older formula | Helps estimate insulin resistance from fasting glucose and insulin | Calculated value; not a standalone lab test |
| HOMA2-IR | Model-derived insulin resistance estimate | Updated nonlinear assessment of insulin resistance | Calculated value; requires HOMA2 calculator and provider interpretation |
| HOMA2-%B | Model-derived beta-cell function estimate | Helps evaluate pancreatic insulin-output pattern | Calculated value; not a stand-alone measure of pancreatic health |
| HOMA2-%S | Model-derived insulin sensitivity estimate | Helps show how responsive tissues may be to insulin | Calculated value; requires calculator and clinical context |
| Hemoglobin A1c | Estimated average glucose over about three months | Helps evaluate longer-term glucose exposure | May be affected by anemia, kidney disease, pregnancy, and blood cell turnover |
| Lipid Panel with Triglycerides | Cholesterol and triglyceride levels | Triglycerides may add cardiometabolic context | Affected by fasting status, diet, alcohol, and medications |
| Comprehensive Metabolic Panel | Glucose, kidney markers, liver enzymes, electrolytes, and proteins | Provides broader metabolic context | Does not directly measure insulin |
| hs-CRP | High-sensitivity C-reactive protein | May provide cardiometabolic inflammation context | Non-specific marker; may rise with infection, injury, or inflammation |
| Apolipoprotein B | Number of atherogenic lipoprotein particles | May help assess cardiovascular risk with insulin resistance | Not a glucose marker |
| Uric Acid | Purine metabolism marker | May be associated with metabolic patterns | Non-specific; affected by diet, kidney function, and medications |
Essential testing may be appropriate for people who want a first look at glucose and insulin regulation. Suggested tests may include:
Advanced testing may be considered when someone has risk factors such as family history of type 2 diabetes, metabolic syndrome, PCOS, weight-loss resistance, elevated triglycerides, fatigue, or previous abnormal glucose results.
Comprehensive testing may be appropriate when the goal is a broader cardiometabolic review or when prior testing shows concerning patterns.
For people with a history of pancreatitis, pancreatic surgery, cystic fibrosis, unexplained glucose swings, or provider concern for pancreatic-related glucose dysregulation, additional tests may be considered by a healthcare provider.
Follow-up testing may be considered every 3 to 6 months when tracking lifestyle changes, weight changes, medication changes, or provider-directed metabolic monitoring. Testing frequency should be based on personal health history and healthcare provider guidance.
For any HOMA-style calculation, use fasting values from the same blood draw whenever possible.
Core inputs include fasting glucose, fasting insulin, and/or C-peptide. A lipid panel can provide triglyceride context for the broader pattern.
The older HOMA-IR formula can be calculated manually. HOMA2-IR, HOMA2-%B, and HOMA2-%S should not be calculated by hand using the older formula. HOMA2 uses a nonlinear model and should be generated with a validated HOMA2 calculator.
When glucose is reported in mg/dL:
HOMA-IR = fasting insulin × fasting glucose ÷ 405
Example:
95 × 12 ÷ 405 = 2.81
When glucose is reported in mmol/L:
HOMA-IR = fasting insulin × fasting glucose ÷ 22.5
When glucose is reported in mg/dL:
HOMA-%B = 360 × fasting insulin ÷ (fasting glucose − 63)
Example:
360 × 12 ÷ (95 − 63)
4,320 ÷ 32 = 135%
When glucose is reported in mmol/L:
HOMA-%B = 20 × fasting insulin ÷ (fasting glucose − 3.5)
This is the older HOMA beta-cell estimate. It is not the same as HOMA2-%B.
In the older model, insulin sensitivity is commonly estimated as the reciprocal of insulin resistance:
HOMA-%S ≈ 100 ÷ HOMA-IR
Example:
100 ÷ 2.81 = 35.6%
To calculate true HOMA2 values:
Important calculation note: Do not treat HOMA-IR and HOMA2-IR as interchangeable. HOMA-IR is an older formula-based estimate. HOMA2-IR is generated through the updated nonlinear HOMA2 model.
Lab results are interpreted against reference ranges, but reference ranges are not the same as a personal diagnosis. A result may be inside the standard range and still be worth discussing if symptoms, trends, or related markers suggest a pattern.
Results may vary based on:
A single abnormal result does not always mean disease. A normal result does not always rule out a health concern. Trends over time and pattern-based interpretation are often more useful than a single isolated value.
Ulta Lab Tests helps patients access many lab tests directly online where available. Testing is performed through established laboratory networks such as Quest Diagnostics, where applicable. Patients can review transparent pricing before ordering, and no insurance is required.
Results are delivered securely online. Patients can use their lab results to have more informed conversations with their healthcare provider about glucose regulation, insulin resistance, beta-cell output, insulin sensitivity, cardiometabolic risk, and long-term wellness.
Ulta Lab Tests does not diagnose, treat, cure, or prevent disease. Lab testing provides information that should be interpreted with a qualified healthcare provider.
Many glucose and insulin-related tests require fasting. Check the specific test instructions before ordering.
General preparation may include:
Do not stop prescribed medications unless instructed by your healthcare provider.
HOMA2-IR is a calculated estimate of insulin resistance. It helps show how much resistance the body may have to insulin’s effects. A higher value may suggest that the body is working harder to maintain glucose balance, but it should be interpreted with fasting glucose, insulin or C-peptide, triglycerides, A1c, symptoms, and medical history.
HOMA2-%B estimates beta-cell function. Beta cells are the insulin-producing cells of the pancreas. This marker may help show whether the pancreas appears to be producing more or less insulin in relation to the glucose level. It should not be interpreted alone because high or low results can mean different things depending on the full pattern.
HOMA2-%S estimates insulin sensitivity. Insulin sensitivity describes how responsive the body’s cells are to insulin. A lower HOMA2-%S may suggest reduced insulin sensitivity, while a higher value may suggest more efficient insulin response. It is most useful when reviewed with HOMA2-IR and HOMA2-%B.
No. HOMA2 uses nonlinear model calculations and should be generated with a validated HOMA2 calculator. The older HOMA-IR formula can be calculated manually using fasting glucose and fasting insulin, but that result is not the same as HOMA2-IR. HOMA2-%B and HOMA2-%S also require the HOMA2 model.
HOMA2 requires fasting glucose with fasting insulin or fasting C-peptide. These should ideally come from the same fasting blood draw. Triglycerides, A1c, a lipid panel, and a comprehensive metabolic panel may provide additional context when reviewing the broader glucose and insulin pattern.
Yes. Fasting glucose can remain normal in early insulin resistance because the pancreas may produce more insulin to keep glucose controlled. This is why fasting insulin, C-peptide, triglycerides, A1c, and HOMA-style calculations may provide additional insight beyond fasting glucose alone.
HOMA-IR is the older formula-based estimate using fasting glucose and fasting insulin. HOMA2-IR is generated by the updated HOMA2 model, which uses nonlinear calculations and can account for more complex glucose-insulin physiology. The two should not be treated as identical.
C-peptide is released when the pancreas makes insulin. Because it can reflect the body’s own insulin production, it may be helpful when evaluating beta-cell output, especially when insulin dynamics are complex. C-peptide should be interpreted with glucose, kidney function, medication history, and clinical context.
No. HOMA2 may help healthcare providers assess insulin resistance, beta-cell function, and insulin sensitivity, but it is not a stand-alone diagnostic test. Diabetes and prediabetes are diagnosed using established clinical criteria and should be evaluated by a qualified healthcare provider.
Retesting may be considered every 3 to 6 months when monitoring metabolic changes, lifestyle changes, or provider-directed care plans. The right timing depends on your medical history, symptoms, medications, and prior results. Ask your healthcare provider what interval is appropriate for you.
Ask whether your fasting glucose, insulin, C-peptide, triglycerides, and A1c appear consistent with normal glucose regulation, early insulin resistance, late insulin resistance, hypoglycemia patterns, or another concern. Also ask whether follow-up testing, lifestyle changes, or additional clinical evaluation may be appropriate.
Fasting glucose is useful, but it does not always show the full glucose-insulin story. HOMA2-IR, HOMA2-%B, and HOMA2-%S help organize fasting glucose with insulin or C-peptide into a more informative assessment of insulin resistance, beta-cell output, and insulin sensitivity.
This matrix-based approach may help identify patterns that routine glucose testing alone can miss, including early insulin resistance, late insulin resistance, reactive hypoglycemia patterns, type 2 diabetes patterns, and pancreatic-related glucose dysregulation patterns.
Ulta Lab Tests makes it easier to access relevant lab testing so patients can better understand their results and have more informed conversations with their healthcare provider. Explore glucose, insulin, C-peptide, A1c, lipid, and cardiometabolic lab testing options on UltaLabTests.com.
Lab testing is informational and should always be reviewed with a qualified healthcare provider.
HOMA2-IR, HOMA2-%B, and HOMA2-%S are calculated markers that help estimate insulin resistance, beta-cell output, and insulin sensitivity using fasting glucose with fasting insulin or C-peptide. When reviewed together with triglycerides, A1c, and related metabolic markers, they may help identify glucose dysregulation patterns that routine fasting glucose testing alone can miss.
Related lab tests: fasting glucose, fasting insulin, C-peptide, hemoglobin A1c, lipid panel with triglycerides, comprehensive metabolic panel, hs-CRP, ApoB, and uric acid.
How Ulta Lab Tests helps: Ulta Lab Tests provides direct access to many glucose, insulin, C-peptide, A1c, lipid, and cardiometabolic lab tests so patients can better understand their results and discuss them with a qualified healthcare provider.
Disclaimer: Lab testing is informational and should be reviewed with a qualified healthcare provider. It does not replace medical advice, diagnosis, or treatment.
Glucose Test
Insulin Test
C-Peptide Test
Insulin and Glucose Panel
Suspected Insulin Resistance Panel
A1c Test
A1c Test with eAG
Blood Sugar Test Panel
Lipid Panel Test
Lipid Panel Test with Reflex to Direct LDL
Lipid Panel with Direct LDL
Apolipoprotein B Test
hs-CRP Test
Uric Acid Test
Comprehensive Metabolic Panel Test - CMP
Lipid Panel and Comprehensive Metabolic Panel-CMP
Urinalysis Complete Test
Urinalysis Complete Test with Reflex to Culture
Glucose Tolerance Test 2 Specimens 75g
Glucose Tolerance Test 3 Specimens 75g
Glucose Tolerance Test 4 Specimens
Insulin Response to Glucose Test 2 Specimens
Insulin Response to Glucose Test 4 Specimens
Insulin Response to Glucose Test 5 Specimens
C-Peptide Response to Glucose Test 2 Specimens
C-Peptide Response to Glucose Test 3 Specimens
C-Peptide Response to Glucose Test 4 Specimens
Diabetes Tests
Insulin Resistance Tests
Diabetes Screening
Blood Sugar Monitoring
Metabolic Syndrome Tests
Diabetes Management
Heart & Cardiovascular Tests
Cholesterol Tests
Cardio IQ Tests
General Health Tests
Baseline Biomarkers
Inflammation Tests
Chronic Inflammation Tests
Pancreatitis Tests
Nutrition & Diet Tests
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
